News

The company said it will discontinue clinical development of the drug in ulcerative colitis (UC). The Origin phase 2a study demonstrated that GLPG1205 did not differentiate from the

Ofev has been recommended for use within the National Health Service (NHS) in England and Wales in adult patients only if the person has moderate disease with a

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of November 16, 2016 . The Marketing Authorisation Application (MAA) for brodalumab in psoriasis was

Encore Vision president and CEO Bill Burns said: "We are pleased to confirm that 75 subjects have been enrolled in the study and to date, there have been

AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation will provide funding and expertise to the collaboration with Imperial College London, the University of Cambridge and University College London (UCL).

IX-01, an investigational compound, was originally discovered at Pfizer’s Sandwich research and development site in the UK. Under the randomized, double-blind, placebo controlled phase 2a study, Ixchelsis investigated

Based on the FDA’s response, XTL plans to file its IND, and in the coming quarters initiate a global clinical trial for hCDR1 in the treatment of systemic

Perrigo was the authorized generic distributor of these products from 2005 to 2013 before the agreement was terminated. Generic and brand sales of Retin-A, which is indicated for

Data generated from the analysis are expected to expand the understanding of multiple myeloma biology and potentially identify mechanisms of sensitivity or resistance to proteasome inhibitor treatment, which